Source: iQoncept / Shutterstock
ARS Pharmaceuticals (NASDAQ:SPRY) has recently unveiled its triumph for the fourth quarter of 2023.
- Reporting earnings per share of -7 cents, ARS Pharmaceuticals exceeded the forecasted EPS of -14 cents by analysts.
- The quarter did not witness any reported revenue from the company.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/spry-stock-earnings-ars-pharmaceuticals-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
